{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-017541","form_type":"8-K","ticker":"ACH","cik":"0000075252","company_name":"ACCENDRA HEALTH INC/VA/","filed_at":"2026-02-19T23:59:59+00:00","discovered_at":"2026-05-14T18:02:37.644421+00:00","generated_at":"2026-05-16T01:53:10.994007+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Accendra Health Q4 revenue $709M; GAAP loss narrows to $9.4M; completes P&HS sale","bullets":["Revenue from continuing ops $709M (up 2% YoY); full-year revenue $2.76B (+3% YoY).","GAAP loss from continuing ops improved to $9.4M from $331.9M in Q4 2024.","Adjusted net income $16.7M ($0.21/share) vs $25.0M ($0.32) prior year.","Adj. EBITDA $90M vs $102.5M; free cash flow $18.3M vs $30.1M.","Completed sale of Products & Healthcare Services on Dec 31, 2025; focusing on cost control and balance sheet."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-017541","json":"https://secwatch.observer/filing/0001104659-26-017541.json","markdown":"https://secwatch.observer/filing/0001104659-26-017541.md","text":"https://secwatch.observer/filing/0001104659-26-017541.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/75252/000110465926017541/0001104659-26-017541-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/75252/000110465926017541/omi-20260219x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T01:53:10.994007+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}